<DOC>
	<DOCNO>NCT01903733</DOCNO>
	<brief_summary>The objective study provide long term access bosutinib treatment ass long term safety , tolerability duration clinical benefit , without formal hypothesis test ; therefore , formal primary endpoint .</brief_summary>
	<brief_title>Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia ( CML ) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Only subject previously participate two specific study eligible enroll study . Enrollment open subject previously enrol study B1871006 B1871008 . All subject exclude unless previously participate study B1871006 B1871008 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Subjects</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Bosutinib</keyword>
	<keyword>Extension</keyword>
</DOC>